the Role of Probiotic in Protein Metabolism

Launched by WECARE PROBIOTICS CO., LTD. · Mar 6, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a specific probiotic, Weizmannella coagulans BC99, on healthy athletes. The goal is to see how this probiotic might help improve their muscle health, athletic performance, and how their bodies digest and use protein. Over six weeks, researchers will look at changes in things like digestive enzymes, amino acids (the building blocks of proteins), body composition (like muscle and fat), and hormone levels to understand how probiotics could help athletes with their training and nutrition.

To participate in this study, you need to be a healthy adult between 18 and 35 years old, not have any allergies to protein products, and have a healthy weight (with specific guidelines). You should also not have any major health issues like heart disease or diabetes. If you join, you can expect to take the probiotic for six weeks while researchers monitor your health and performance. This study is important because it could provide valuable insights into how probiotics might improve nutrient absorption, especially for those who have trouble digesting food.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Voluntarily, in writing, and signing the informed consent form, agreeing to participate in this study;
• • 2. Agree to abide by the protocol and study restrictions;
• • 3. The subject is not allergic to protein products;
• • 4. Male or female subjects aged 18 to 35 years old (including 18 and 35 years old);
• • 5. Male subjects should weigh no less than 50 kilograms. Female subjects must weigh no less than 45 kg. Body mass index (BMI) = weight (kg)/height (m)2, body mass index is in the range of 19.0 to 24.0 kg/m2;
• • 6. No history of hidden risks of cardiovascular and cerebrovascular diseases, hypertension, diabetes, liver/kidney function, etc. and metabolic abnormalities.
• Exclusion Criteria:
• • 1. Patients with allergies and immune deficiency;
• • 2. Donated blood or lost a large amount of blood (≥200 mL) within 3 months before taking the trial drug;
• • 3. Other systemic diseases, including cardiovascular disease, lung disease, liver disease, kidney disease and other serious lesions of important organs, severe metabolic diseases (diabetes, thyroid disease), severe immune system diseases; no cardiovascular and cerebrovascular diseases, hypertension , diabetes, liver/kidney function and other hidden dangers and metabolic abnormalities.
• • 4. Drugs that affect intestinal flora (including antibacterial drugs, microecological preparations, intestinal mucosal protective agents, Chinese patent medicines, etc.) have been used continuously for more than 1 week within 1 month before screening;
• • 5. Subjects judged by other researchers to be unfit to participate.